IN8bio Presents Biologic Correlative Data From The INB-200 Phase 1 Trial In Newly Diagnosed Glioblastoma At The Society For Immunotherapy Of Cancer 38th Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
IN8bio, Inc. (NASDAQ:INAB) presented new biological correlative data from the ongoing Phase 1 clinical trial of INB-200 targeting newly diagnosed glioblastoma multiforme (GBM) at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting. The data demonstrated the ability of INB-200, a DeltEx drug-resistant immunotherapy (DRI) gamma-delta T cell therapy, to induce T cell persistence and a sustained immune response. The company will present updated patient, survival and enrollment data from the study at the Society for Neuro-Oncology (SNO) Annual Meeting on November 17, 2023.
November 06, 2023 | 1:47 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
IN8bio's presentation of positive data from the ongoing Phase 1 trial of INB-200 could potentially boost investor confidence in the company's innovative gamma-delta T cell therapies. The company's focus on developing treatments for solid tumors, such as GBM, could position it well in the oncology market.
The positive data from the Phase 1 trial of INB-200 demonstrates the potential of IN8bio's innovative gamma-delta T cell therapies. This could attract more investors to the company, potentially driving up the stock price in the short term. Furthermore, the company's focus on developing treatments for solid tumors, such as GBM, could position it well in the oncology market, which could have a positive impact on the stock price in the long term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100